Why Is CASI Pharmaceuticals, Inc. Ordinary Shares (CASI) Stock Down 68.7% Today?

CASI Pharmaceuticals (CASI) stock crashed hard Wednesday, dropping 68.7% to $0.265 per share on massive volume of 3.8M shares—193.8x the average daily volume. The biotech company received a buyout offer for its China business, a move that spooked investors despite representing potential strategic value. Trading in a $0.2368-$0.3749 range, CASI has now wiped out more than two-thirds of shareholder value in a single session. The brutal decline answers a critical question for CASI holders: why is CASI stock down today, and what does this deal mean for the company's future?

What's Driving CASI Stock Down 68.7% Today

The catalyst is straightforward but complex: CASI received a buyout offer for its China business operations. On the surface, this should be positive—a buyer offering to take an underperforming division off the company's hands typically creates optionality. But the market's 68.7% hammering suggests investors are pricing in a worst-case scenario for what remains.

Here's the problem: China operations have historically represented a significant revenue stream for CASI, particularly through partnerships and commercialization deals in the region. A forced or unfavorable buyout of that division could cripple cash flow and force the company to restructure its pipeline investments. The timing also matters. At $0.265, CASI trades well below any reasonable valuation multiple, suggesting the market is questioning whether the core business—focused on leukemia and lymphoma treatments like EVOMELA injection—can survive standalone.

The scale of the selloff also reveals something darker: potential dilution. If CASI needs to raise capital to fund operations post-China sale, existing shareholders face significant dilution risk. Combined with the loss of a revenue-generating business unit, this created a perfect storm for sellers.

CASI Stock Key Levels to Watch

Current price: $0.265. Intraday range: $0.2368 to $0.3749. Previous close: $0.80.

Support levels: $0.2368 (today's low and potential floor if panic selling stops). $0.20 represents a psychological round level where long-term holders may defend. Below that, $0.15 becomes the next technical support.

Resistance: $0.3749 (today's high—if CASI bounces, this is the first ceiling). $0.50 represents the halfway point back to yesterday's close and would require significant positive news to reach. Yesterday's $0.80 close is now psychologically unreachable on any near-term bounce.

Volume context: 3.8M shares traded today versus the typical 19.6k average daily volume. This 193.8x surge confirms capitulation selling rather than algorithmic moves. When volume spikes this hard on a down day in a micro-cap biotech, it usually signals exhaustion—meaning the worst of the selling may be priced in, but that's not a buying signal.

52-week positioning: CASI is now trading near multi-year lows. Without access to exact 52-week highs/lows, the dramatic move suggests the stock has likely broken through several years of support levels.

What Analysts Say About CASI Stock

HC Wainwright & Co. maintains a Buy rating on CASI, per November 2023 coverage. However, that rating was issued well before today's buyout announcement and China business complications. The firm's price target is not stated in available data, but a Buy rating at $0.265 requires significant upside assumptions.

Consensus is murky given the breaking news nature of the China deal. Before today, CASI likely carried mixed-to-cautious sentiment from the analyst community—typical for a micro-cap biotech trading at penny stock levels. No recent downgrades are mentioned in available coverage, but that's likely because few analysts follow CASI closely enough to react instantly.

The key takeaway: analyst consensus means very little here. CASI is too small to command broad coverage, and most ratings were issued under pre-deal assumptions. HC Wainwright's Buy is now underwater on a historical basis and will likely be subject to review pending details on the China sale terms.

What's Next for CASI Stock

The buyout offer needs more clarity. Key questions: Who is buying the China business? At what price? Will the sale provide enough cash runway for CASI to continue operating, or does it guarantee dilutive financing?

Bull case: CASI negotiates a favorable price for the China asset, uses proceeds to fund clinical trials for EVOMELA and other pipeline candidates, and positions itself for a strategic partnership or acquisition at higher valuations. This scenario plays out over 12-24 months and could drive CASI to $0.50-$1.00 as pipeline data improves.

Bear case: The China sale closes at a fire-sale price, provides minimal cash, and CASI is forced into dilutive equity raises or debt restructuring. The company continues burning cash without generating meaningful EVOMELA sales, and eventually faces insolvency or reverse merger. This scenario keeps CASI pinned below $0.30 indefinitely.

Next catalyst: CASI will issue a press release detailing the buyout offer terms, including purchase price, deal timeline, and board recommendation. This guidance could trigger a 20-50% bounce if terms are better than feared, or accelerate selling if they're worse. Beyond that, Q2 earnings and updated pipeline guidance will be critical checkpoints. Without a specific date available, monitor CASI's investor relations page for imminent announcements.

Frequently Asked Questions

Why is CASI stock down 68.7% today?
CASI Pharmaceuticals received a buyout offer for its China business operations. The market interpreted this as a negative signal about the company's viability standalone and priced in risks of dilutive financing and reduced cash flow. The 68.7% crash reflects capitulation selling as investors fled a micro-cap biotech with deteriorating fundamentals.

Is CASI stock a buy at $0.265?
That depends on your risk tolerance and investment thesis. HC Wainwright maintains a Buy rating, suggesting upside exists if CASI executes on pipeline milestones post-China sale. However, at penny stock levels with unresolved deal terms, this is a highly speculative position. Position sizing is critical—only risk capital you can afford to lose entirely.

What is CASI Pharmaceuticals' stock price target?
HC Wainwright's target is not currently disclosed in available data, but the Buy rating implies meaningful upside from current levels. Historically, CASI targets have ranged from $2-$4 on optimistic pipeline assumptions, but those were issued at higher stock prices. Post-China deal restructuring, analyst targets will need significant revision.

What is CASI's market cap now?
With the stock at $0.265, CASI's market cap has compressed dramatically. Exact figures depend on fully diluted share count, but the company is now effectively a micro-cap biotech worth tens of millions at best—not hundreds of millions.

When is CASI's next earnings report?
Monitor the investor relations page for Q2 earnings guidance. Typically, biotech companies report quarterly, so expect updates within the next 30-60 days depending on fiscal calendar alignment.

Bottom Line: CASI Selloff Reflects Existential Risk

The 68.7% crash is brutal but not surprising given CASI's position. A micro-cap biotech with a revenue-dependent China business receiving a buyout offer signals distress, not opportunity. The company is being forced to restructure, and shareholders are rightly concerned about dilution and cash burn.

Short-term bounce potential exists if deal terms exceed expectations or if oversold technicals trigger short covering. But until CASI provides concrete details on deal pricing, use-of-proceeds, and pipeline milestones, the risk remains heavily skewed to the downside. This is a story for risk-tolerant traders with a multi-year time horizon—not for income or stability-seeking investors.

Watch support at $0.2368 closely. If CASI breaks below that level on similar volume spikes, the next stop could be penny stock purgatory or delisting risk.